Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort
about
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney diseaseRationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.Pathophysiology of copeptin in kidney disease and hypertensionKidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patientsPredictors of autosomal dominant polycystic kidney disease progressionTwenty-four-hour urine osmolality as a physiological index of adequate water intake.Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression.Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study.Vasopressin and disruption of calcium signalling in polycystic kidney disease.Biomarkers and surrogate endpoints in kidney disease.Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014).An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease.Diagnostic Evaluation as a Biomarker in Patients with ADPKD.Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?New treatment paradigms for ADPKD: moving towards precision medicine.Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients.Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease
P2860
Q26798115-7793081D-7E94-45FD-9C08-7E6E2A40BDF1Q33702355-3A3D3D35-F5C7-4E10-9606-E57BE0A148A8Q33792317-ABAD3293-6745-4C3B-A786-B2E8E6DE9DB7Q34124758-9BB4F418-9EBE-4536-A9F0-0C0AC81D9FE3Q34427678-7BFE0B58-8315-4CF5-A151-86FD8139E3F0Q35240784-B344C859-6494-41CB-9A83-CE36666C30F6Q35559202-4D55E060-41A6-40C2-94E3-5D925ABFA877Q35658585-1A0857B4-28AF-4C37-8282-6AA4A80A58DDQ35962991-1ACC7E51-AB31-43D4-A1B7-56E67971DE49Q36284659-244C4D82-CF3E-4B98-92BF-52ABC235A4FFQ36315686-9FA34872-4231-40BD-AD97-8DD84D80FFB4Q36329310-66BFFB69-A23B-4232-B6B9-A1691996C319Q37278044-AE77738D-DA56-48AD-B05D-B9E898341F08Q37650894-15E3B2F1-99EE-4C71-966A-74C5FAE5D94BQ38540557-B8683040-97A4-4D08-9DB5-054C6E4116F7Q38978474-CCF3E738-DE30-45FD-A787-C512E74BE625Q40123527-F59824AF-0F97-4FA0-AD0A-DC7F828F84F9Q48216298-82C71010-07BF-4B8A-81B8-E38B48829D93Q49494721-BA5B0FA2-A463-46A0-94B0-581017E60094Q50048323-A8C1BA9C-4F25-4DB8-A008-2C2670508562Q50350995-20A58DAC-47E5-4720-A569-AE07E69C385BQ51213724-250E19A1-6338-4FA2-932F-B51CA9157220Q52850208-DDE05522-DD28-4666-8FD5-7780B76AD18DQ53603650-42F81F4E-8373-48C3-83C1-5937E907AEA2Q55003026-7FD0EEC5-E095-4D2B-9184-4A45A93EADBBQ57815283-BEA9ACF9-BFD8-48D9-BCAF-B0D84220C89C
P2860
Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Relationship of copeptin, a su ...... results from the CRISP cohort
@ast
Relationship of copeptin, a su ...... results from the CRISP cohort
@en
type
label
Relationship of copeptin, a su ...... results from the CRISP cohort
@ast
Relationship of copeptin, a su ...... results from the CRISP cohort
@en
prefLabel
Relationship of copeptin, a su ...... results from the CRISP cohort
@ast
Relationship of copeptin, a su ...... results from the CRISP cohort
@en
P2093
P2860
P1476
Relationship of copeptin, a su ...... results from the CRISP cohort
@en
P2093
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP
Esther Meijer
James E Bost
Joachim Struck
Michael F Flessner
Ron T Gansevoort
Vicente E Torres
Wendy E Boertien
P2860
P304
P356
10.1053/J.AJKD.2012.08.038
P577
2012-10-22T00:00:00Z